| |
著者: Ben De Pauw, Thomas J Walsh, J Peter Donnelly, David A Stevens, John E Edwards, Thierry Calandra, Peter G Pappas, Johan Maertens, Olivier Lortholary, Carol A Kauffman, David W Denning, Thomas F Patterson, Georg Maschmeyer, Jacques Bille, William E Dismukes, Raoul Herbrecht, William W Hope, Christopher C Kibbler, Bart Jan Kullberg, Kieren A Marr, Patricia Muñoz, Frank C Odds, John R Perfect, Angela Restrepo, Markus Ruhnke, Brahm H Segal, Jack D Sobel, Tania C Sorrell, Claudio Viscoli, John R Wingard, Theoklis Zaoutis, John E Bennett, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
雑誌名: Clin Infect Dis. 2008 Jun 15;46(12):1813-21. doi: 10.1086/588660.
Abstract/Text
BACKGROUND: Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies.
METHODS: After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved.
RESULTS: The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only.
CONCLUSIONS: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
PMID 18462102 Clin Infect Dis. 2008 Jun 15;46(12):1813-21. doi: 10.1086/588660.
|
